Lisa Maher, MD

International Lipid Expert Panel Recommendations and RACING Trial

Video content above is prompted by the following:

The International Lipid Expert Panel recommends combining therapies as a first-line treatment approach for patients who have elevated LDL-C and a very high risk for a cardiovascular event.

Videos

Pediatric lipid screening is crucial for early detection and management of dyslipidemia, which can prevent cardiovascular diseases later in life. Current guidelines recommend universal lipid screening for children between ages 9-11 and 17-21, with selective screening for those with risk factors. However, implementation remains inconsistent due to barriers such as lack of awareness and time constraints in clinical practice. To improve uptake, strategies include integrating screening into routine pediatric visits, utilizing electronic health records for reminders, and educating healthcare providers and families about the importance and benefits of early lipid screening.

Panelists discuss how the International Lipid Expert Panel advocates for combination therapy as initial treatment in patients with elevated LDL-C and very high cardiovascular risk rather than sequential monotherapy.

Pediatric Lipid Treatment Recommendations

What are the treatment recommendations for children? How early can you start a statin?

Panelists discuss how statin therapy can be initiated in children with familial hypercholesterolemia as early as 8 to 10 years old, following careful evaluation and lifestyle interventions.

Data Analysis: State of LDL-C Control in Patients With ASCVD

This analysis from the Family Heart Foundation examined the state of LDL-C control in X number of patients with ASCVD. Can you please provide an overview?

Panelists discuss how analysis of the Family Heart Foundation’s database provides insights into real-world LDL-C control rates among patients with ASCVD, highlighting opportunities for improved lipid management.

Role of Lp(a) in ASCVD Risk

What is the role played by lipoprotein(a) (Lp[a]) in developing ASCVD?

Panelists discuss how Lp(a), a distinct lipoprotein particle from LDL, independently contributes to ASCVD risk through its unique structural properties and atherogenic potential.

Lisa Maher, MD

Articles